Roche Holding Ltd
ROG
ISIN CH0012032048 / Valor 1203204
Roche Holding Ltd
UMushroom community rating:
About company
Roche Holding Ltd is a global healthcare company known for being one of the largest biotech companies and a leading supplier of in-vitro diagnostics. The company is an innovator in various disease areas such as oncology, neurology, infectious diseases, and ophthalmology. Roche has established partnerships with forward-thinking organizations that share the belief in the power of cutting-edge science and technology to enhance human health.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (14.08.2024):
Group Sales and Margin Trends
In the first quarter of 2023, Roche Holding Ltd reported group sales of CHF 58.7 billion, reflecting a slight decrease of 1% compared to the previous year. Despite the challenges posed by the COVID-19 pandemic, the company managed to maintain a strong performance across its various business segments.
Core Operating Profit
Roche Holding Ltd's core operating profit for Q1 2023 stood at CHF 58.7 billion, marking a 1% decline from the previous year. This slight decrease was attributed to the ongoing impact of the pandemic on certain business operations, although the company still demonstrated resilience in its financial performance.
Core Earnings per Share
For the first quarter of 2023, Roche Holding Ltd reported core earnings per share of CHF 18.57, which represents a 6% increase compared to the same period in the previous year. This growth in earnings per share highlights the company's ability to generate value for its shareholders despite external challenges.
Operating Free Cash Flow
Roche Holding Ltd achieved an operating free cash flow of CHF 15.8 billion in Q1 2023, reflecting a 4% increase from the previous year. This positive cash flow performance underscores the company's strong operational efficiency and effective cash management strategies.
Dividend Increases
In line with its commitment to returning value to shareholders, Roche Holding Ltd announced a dividend increase for the 37th consecutive year in Q1 2023. The gross dividend for Roche was raised by 2%, further solidifying the company's reputation for consistent and reliable dividend payouts.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
197561 M
Market cap (USD)
831,771
Daily traded volume (Shares)
254 / 249.1
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
smail alijagic
Vladimir Jovicic
R B
EQUITIES OF THE SAME SECTOR
